Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 84 Shiller PE Ratio is 835.86 as of Aug. 07, 2026, which is 76% below its 10-year median of 3,460.00. GuruFocus rates CAMRF with a GF Score™ of 84/100 and a GF Value™ of $67.25 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 171 Biotechnology companies, Camurus AB ranks worse than 98.83% on this metric.
As of today (2026-08-07), Camurus AB's current share price is $58.51. Camurus AB's E10 for the quarter that ended in Jun. 2026 was $0.07. Camurus AB's Shiller PE Ratio for today is 835.86.
The historical rank and industry rank for Camurus AB's Shiller PE Ratio or its related term are showing as below:
CAMRF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 894.35 Med: 3460 Max: 3860
Current: 968.31
During the past years, Camurus AB's highest Shiller PE Ratio was 3860.00. The lowest was 894.35. And the median was 3460.00.
CAMRF's Shiller PE Ratio is ranked worse than 98.83% of 171
companies
in the Biotechnology industry
Industry Median: 32.08
vs CAMRF: 968.31
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Camurus AB's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.426. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.07 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Camurus AB (OTCPK:CAMRF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Camurus AB Shiller PE Ratio Related Terms
Camurus AB Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison
For the Biotechnology subindustry, Camurus AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Camurus AB's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Camurus AB's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Camurus AB (CAMRF) has a Shiller PE Ratio of 835.86 as of Aug. 07, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Camurus AB and its competitors. This is 76% below median its historical median of 3,460.00. Over the past decade, Camurus AB's Shiller PE Ratio has ranged from 894.35 to 3,860.00. According to the industry distribution chart, Camurus AB ranks #169 out of 171 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Camurus AB's Shiller PE Ratio too high?
Camurus AB's current Shiller PE Ratio of 835.86 is 76% below median its 10-year median of 3,460.00. Over the past 10 years, this metric has ranged from a low of 894.35 to a high of 3,860.00. The Biotechnology industry median Shiller PE Ratio is 32.08. Camurus AB's value of 835.86 is 2505.5% above this industry median. Based on the distribution chart, Camurus AB ranks #169 out of 171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camurus AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Shiller PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #169 out of 171 companies for Shiller PE Ratio. This places Camurus AB in the lower half of its industry. The industry median Shiller PE Ratio is 32.08. Camurus AB's value of 835.86 is 2505.5% above this benchmark. Historically, Camurus AB's own Shiller PE Ratio has ranged from 894.35 to 3,860.00 over the past decade. While the company's 10-year median is 3,460.00 vs. the industry median of 32.08, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 32.08, based on 171 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Shiller PE Ratio of 835.86 is 2505.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 32.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Shiller PE Ratio is 835.86, which is 76% below median its own 10-year median of 3,460.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $67.25, compared to a current price of $58.51 — trading 13% below its estimated fair value. The current Shiller PE Ratio is 835.86, which is 76% below median its 10-year median of 3,460.00 and 2505.5% above the Biotechnology industry median of 32.08. Camurus AB's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Shiller PE Ratio is 835.86 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 13% below its estimated GF Value™ of $67.25.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Shiller PE Ratio: 835.86 (76% below median its 10-year median of 3,460.00)
GF Value™: $67.25 vs. price of $58.51 (13% below fair value)
Industry Position: 2505.5% above the Biotechnology median (#169 of 171)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
84GF Score
Get the complete analysis for CAMRF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
